Objectives: This study aims to investigate neuropathic pain in rheumatologic disorders including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and osteoarthritis (OA) using PainDETECT and to determine its effect on the quality of life in terms of disease activity, functional status, social and emotional functioning. Patients and methods: A total of 150 patients (66 males, 84 females; mean age 48.44±12.22 years; range 25 to 65 years) were included in the study. Of these patients, 50 had OA, 50 had RA, and 50 had AS. Control group consisted of 50 healthy subjects (20 males, 30 females; mean age 48.36±12.68 years; range 25 to 65 years). OA severity was evaluated by Western Ontario and McMasters Universities Index of Osteoarthritis. In RA patients, Disease Activity Score-28 was used for measuring disease activity, and Stanford Health Assessment Questionnaire for functional status. In AS patients, disease activity was assessed by Bath Ankylosing Spondylitis Disease Activity Index and functional status by Bath Ankylosing Spondylitis Functional Index. Neuropathic pain was determined by PainDETECT questionnaire and quality of life by Nottingham Health Profile. Results: Prevalence of neuropathic pain was 44% in OA, 28% in AS, and 18% in RA patients. Compared with control patients, prevalence was higher in OA [Odds ratio=12.46 95% confidence interval (3.89-39.85)] (p=0.00) and AS patients [Odds ratio=4.47 95% confidence interval (1.36-14.76)] (p=0.009). In OA patients, PainDETECT was correlated with Western Ontario and McMasters Universities Index of Osteoarthritis (p=0.00). In all of the patient groups, PainDETECT was correlated with Nottingham Health Profile (p=0.00). Physical mobility subgroup showed the strongest correlation with PainDETECT. Conclusion: Our study demonstrated that neuropathic pain is strongly associated with quality of life in terms of physical mobility, energy, sleep, and social and emotional functions. The disease with highest prevalence of neuropathic pain was OA. A better understanding of neuropathic pain mechanisms in rheumatic diseases will help us find more effective treatment strategies.
Chronic pain is classified as nociceptive (inflammatory) pain and neuropathic pain. Nociceptive pain is caused by stimulation of nociceptors through chronic inflammation. 1 Neuropathic pain is defined as "pain caused by a primary lesion or dysfunction in the nervous system" by International Association for the Study of Pain. 2 Peripheral and central sensitization, inhibition of descending pain inhibitory systems, functional changes in autonomic nervous system and neurotransmitters are important factors in neuropathic pain. 3 Patients describe neuropathic pain as burning, painful, cold or electric shocks and possibly associate it with tingling, pins and needles, numbness or itching. 4 Prevalence of neuropathic pain is not exactly known. Best current estimates of the population prevalence of neuropathic pain come from studies using validated screening tools that detect pain with possible neuropathic features. 5 Previous studies have shown that prevalence of neuropathic pain is around 7-8% in the general population. 6 There are only a few studies that investigated the prevalence of neuropathic pain in rheumatic diseases in the literature.
Neuropathic pain must be correctly diagnosed for optimal treatment, since neuropathic and non-neuropathic pain require different treatment strategies. Several screening tools have been developed to differentiate neuropathic pain from non-neuropathic pain. 7 They also serve as a good clinical record for follow-up of the patients. 4 PainDETECT is a simple, self-administered, useful screening questionnaire, which was designed to evaluate neuropathic signs and symptoms without physical examination. 8 It was developed by Freynhagen et al. 9 to identify neuropathic components in patients with back pain. It was found to be a reliable tool with high sensitivity, specificity, and positive predictive accuracy.
Neuropathic pain is not a single disease, but a syndrome caused by a range of different diseases and lesions, which has a considerable impact on the quality of life (QoL). 8 This study aims to investigate neuropathic pain in rheumatologic disorders including rheumatoid arthritis (RA), ankylosing spondylitis (AS) and osteoarthritis (OA) using PainDETECT and to determine its effect on the QoL in terms of disease activity, functional status, social and emotional functioning. 13 Functional status was determined by using the Stanford Health Assessment Questionnaire. 14 Ankylosing spondylitis patients fulfilled the modified New York criteria. 15 Patients were evaluated by using Assessment of SpondyloArthritis International Society recommendations for core outcome domains for the assessment in AS. 16 Erythrocyte sedimentation rate and C-reactive protein levels were measured. Disease activity was evaluated by using Bath Ankylosing Spondylitis Disease Activity Index. 17 The Bath Ankylosing Spondylitis Functional Index was used for determining functional status. 18 QoL of the patients was assessed by using Nottingham Health Profile (NHP). 19 Presence of neuropathic pain was determined by using PainDETECT questionnaire. 8 The PainDETECT is a simple, self-administered questionnaire, which was developed to detect neuropathic pain in patients with chronic pain. It comprises four dimensions.
PATIENTS AND METHODS
The first dimension contains three items that assess intensity of pain at the moment, the average and the maximum pain intensity during the past four weeks. In the second dimension, patients are asked to mark one of the four graphs that describe their pain course patterns. The third dimension consists of a sensory map representing homunculus along with questions asking to mark the pain zone, a dichotomous item about the presence of radiating pain and showing the direction of radiating pain with an arrow. In the fourth dimension, there are seven questions about the following sensations: burning, tingling or prickling, allodynia, pain attacks, temperature evoked pain, numbness, and pressure-evoked pain. The final score is obtained by summing up the scores of the last three sections with a total score of -1 to 38. Table 3 .
Mean PainDETECT score of OA patients was 12.81±9.99 (Table 2) . PainDETECT was found to be ≥19 in 22 patients (44%). Mean PainDETECT score of RA patients was 8.57±7.34 (Table 2) . PainDETECT was found to be ≥19 in nine patients (18%). Mean PainDETECT score of AS patients was 12.06±9.61 (Table 2) . PainDETECT was found to be ≥19 in14 patients (28%).
According to PainDETECT, the prevalence of neuropathic pain was 44% in OA, 28% in AS, 18% in RA patients, and 8% in controls.
The prevalence of neuropathic pain was higher in patients with OA [odds ratio=12.46 95% confidence interval (3.89-39.85)] (p=0.00) and in patients with AS (odds ratio=4.47 95% confidence interval (1.36-14.76)] (p=0.009), compared with controls (Table 4 ). There was no statistically significant difference between neuropathic pain prevalence of RA and control group [odds ratio=2.52 95% confidence interval (0.72-8.82)] (p=0.14) ( Table 4) .
In OA patients, PainDETECT was correlated with WOMAC A, B, C and WOMAC total (r=0.88, 0.74, 0.95, and 0.96, respectively) (p=0.00) and physical mobility, pain, emotional reactions, sleep, social isolation, and energy subgroups of NHP (r=0.77, 0.76, 0.75, 0.69, 0.66, and 0.63, respectively) (p=0.00). Analyses of correlation coefficients revealed that the strongest relation of PainDETECT was with physical mobility subgroup of NHP.
In AS patients, there was no significant correlation between PainDETECT and Bath Ankylosing Spondylitis Disease Activity Index, and Bath Ankylosing Spondylitis Functional Index (p=0.18, r= -0.19 and p=0.58, r= -0.08, respectively). PainDETECT was related with physical mobility, emotional reactions, social isolation, sleep, energy, and pain subgroups of NHP at high levels (r=0.82, 0.81, 0.80, 0.79, 0.72, and 0.68, respectively) (p=0.00). Analyses of correlation coefficients revealed that the strongest relation of PainDETECT was with physical mobility subgroup of NHP. When the correlation coefficients were analyzed, PainDETECT showed the highest correlation with physical mobility.
In RA patients, there was no significant correlation between PainDETECT and Disease Activity Score-28, and Health Assessment Questionnaire (p=0.18, r=0.17 and p=0.19, r=0.18, respectively). PainDETECT was correlated with physical mobility, pain, emotional 
DISCUSSION
Recent epidemiologic surveys of the general population have suggested that the prevalence of neuropathic pain is 7-8%. 20, 21 To our knowledge, there are few studies in the literature investigating the prevalence of neuropathic pain in patients with rheumatic disorders. In our study, the rate of neuropathic pain was shown as 44% in patients with knee OA. In a 92-case crosssectional study from Japan, the neuropathic pain frequency in patients with knee OA was reported to be 5.4%. 22 Hochman et al. 23 reported prevalence of neuropathic pain symptoms as 28% among older adults with chronic symptomatic knee OA in Canada. They suggested that, in addition to nociceptive mechanisms, neuropathic mechanisms might contribute to chronic pain in patients with OA. Also, previous studies indicated both nociceptive and neuropathic pain in rat models which had surgically and mono-iodoacetate-induced OA. 24, 25 There are possible mechanisms that may explain neuropathic pain in OA. According to McDougall et al., 26 subclinical damage to peripheral nerves may be associated with neuropathic pain in knee OA. In early phases, synovitis produces joint fluid and stimulates free nerve endings in synovium. In late phases of OA, a decreased amount of joint fluid and destruction of the osteochondral junction may induce injury to the nerve endings in this area. 22 Along damaged nerves, increased ectopic activity may occur and contribute to ongoing pain. 23 PainDETECT was demonstrated to be associated with all subgroups of WOMAC in OA patients. This association was found previously in the study of Hochman et al. 27 They reported that neuropathic pain symptoms were significantly associated with greater OA severity.
In our study, prevalence of neuropathic pain was 18% in RA patients. Perrot et al. 28 detected the frequency of neuropathic pain in 37.5% of RA patients, where the neuropathic pain was assessed by using Douleur Neuropathique en 4 Questions. In our study, pain levels did not reflect disease activity and functional status in RA. On the contrary, in the study of Perrot, 28 severity of pain was found to be correlated with disease activity. Different results may be due to our patient selection criteria. We excluded the patients with neurological involvement such as nerve entrapment syndromes, mononeuritis multiplex, and atlantoaxial subluxation.
The prevalence of neuropathic pain was higher (28%) in patients with AS, compared with controls. To the best of our knowledge, ours is the first study to examine the frequency of neuropathic pain in AS in the literature. There is some evidence about neuropathic pain in AS. Wu et al. 29 states that pain in AS is a mixed pain condition that includes a neuropathic pain component. They explained the neuropathic pain mechanism in AS with 'inflammatory radiculopathy'. Local inflammation of the axial spine in AS affects dorsal ramus branches that innervate zygapophyseal joints and periosteum of the vertebral arch, and cause the 'inflammatory radiculopathy' via the action of inflammatory mediators, even without mechanical compression. The relationship of neuropathic pain severity with disease activity and functional impairment has not been studied previously, to our knowledge, in AS population. We found no association between the severity of neuropathic pain, and disease activity and functional status.
To our knowledge, this is the first study to assess the impact of neuropathic pain on QoL domains in rheumatic diseases. We found strong associations between the severity of neuropathic pain and QoL domains including pain, physical mobility, energy, sleep, and social and emotional functions in the patients with OA, RA and AS. Physical mobility subgroup showed the strongest correlation with PainDETECT. These findings show that neuropathic pain has major negative influence on QoL in terms of physical mobility.
This study demonstrates several important observations regarding neuropathic pain in rheumatic disorders. The first important finding was that the disease with the highest prevalence of neuropathic pain was OA, and the severity of neuropathic pain was associated with the severity of OA, confirming the previous data in the literature. Second, neuropathic pain had a
